Bwx Technologies INC

Global Nuclear Technology and Manufacturing Enterprise

Based in DC

🤖

AI Overview

With $1.7M in lobbying spend across 32 quarterly filings, Bwx Technologies INC is a significant lobbying presence. Their lobbying covers 6 issue areas. Active from 2018 to 2025.

$1.7M
Total Spend
8
Years Active
1
Firms Hired
4
Lobbyists Deployed
6
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$160K
2019$200K
2020$200K
2021$200K
2022$200K
2023$230K
2024$240K
2025$240K

Issues Lobbied

Lobbying Firms

Lobbyists

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Budget/Appropriations, Energy, Economics, Aerospace, Immigration and 1 more

  • Issues related to budget and appropriations in regards to nuclear shipbuilding and nuclear energy funding in H.R.3266/S.1609, Energy and Water Development and Related Agencies Appropriations Act, 2018
  • Issues related to the Uranium Barter Program; nuclear indemnification for NASA contractors.
  • Medical isotope issues.
  • Advanced manufacturing and 3-D printing research and development.
  • Issues related to budget and appropriations in regards to nuclear shipbuilding and nuclear energy funding;
  • H.R.5895/S.2975, Energy and Water Development and Related Agencies Appropriations Act, 2019;
  • Issues related to the Uranium Barter Program; nuclear indemnification for NASA contractors.
  • Medical isotope issues.
  • Advanced manufacturing.
  • Issues related to budget and appropriations in regards to nuclear shipbuilding and nuclear energy funding;
  • H.R.5515/S.2987, National Defense Authorization Act for Fiscal Year 2019 (P.L.115-232);
  • H.R.5

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.